Scarica l'app Stockscreener
1.29
3.20%
0.04
Dopo l'orario di chiusura:
1.29
Macrogenics Inc Borsa (MGNX) Ultime notizie
MGNX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit - MarketScreener
Lost Money on MacroGenics, Inc.(MGNX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
ATTENTION MacroGenics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor SuitHagens Berman - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
HC Wainwright Increases Earnings Estimates for MacroGenics - Defense World
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC Wainwright - Defense World
MGNX stock touches 52-week low at $1.88 amid market challenges - Investing.com Australia
MGNX stock touches 52-week low at $1.88 amid market challenges By Investing.com - Investing.com South Africa
MacroGenics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Canada
Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical - openPR.com
Macrogenics Inc (NASDAQ: MGNX) Analysts Prediction On How Much It Could Rise - Stocks Register
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Consensus Price Target from Analysts - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript - Insider Monkey
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook - Investing.com Canada
StockNews.com Downgrades MacroGenics (NASDAQ:MGNX) to Hold - Defense World
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook By Investing.com - Investing.com South Africa
MacroGenics Inc’s 2024 Earnings Call Highlights - TipRanks
MacroGenics axes ADC drug following Phase II failure in prostate cancer - Yahoo
Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahea - GuruFocus.com
Stifel maintains Hold on MacroGenics stock, price target at $6 By Investing.com - Investing.com Canada
Citizens JMP maintains MacroGenics stock with Market Outperform By Investing.com - Investing.com South Africa
Citizens JMP maintains MacroGenics stock with Market Outperform - Investing.com India
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates - MSN
MacroGenics Reports 2024 Financial Results and Progress - TipRanks
Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses - Yahoo Finance
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript - Yahoo
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
MACROGENICS Earnings Results: $MGNX Reports Quarterly Earnings - Nasdaq
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations - Investing.com India
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations By Investing.com - Investing.com UK
MacroGenics Inc. (MGNX) reports earnings - Quartz
MacroGenics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MacroGenics Inc Provides Update On Corporate Progress And 2024 Financial Results - Marketscreener.com
Macrogenics Inc (MGNX) Reports Q4 Revenue of $150 Million, Surpa - GuruFocus
MACROGENICS INC SEC 10-K Report - TradingView
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - GlobeNewswire
MacroGenics Triples Revenue to $150M as Cancer Drug Pipeline Advances - StockTitan
MGNX stock touches 52-week low at $2.15 amid sharp annual decline - Investing.com Australia
Macrogenics Stock Drops 77% After Study Deaths - The Wall Street Journal
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):